Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could presage further deals in STAT6, where ...
Hosted on MSN16d
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and ...
Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and ...
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback